NPI: 1861447179 · MILWAUKEE, WI 53215 · Hematology & Oncology Physician · NPI assigned 05/24/2006
Authorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
| Authorized Official | RICHARDSON, KARA (VP MANAGED HEALTH) |
| NPI Enumeration Date | 05/24/2006 |
Other providers sharing the same authorized official: RICHARDSON, KARA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 992,545 | $24.57M |
| 2019 | 1,057,499 | $24.83M |
| 2020 | 968,194 | $23.10M |
| 2021 | 1,220,791 | $28.71M |
| 2022 | 1,159,207 | $27.07M |
| 2023 | 1,191,712 | $29.61M |
| 2024 | 857,066 | $24.15M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 184,504 | 158,337 | $13.86M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 172,425 | 147,199 | $12.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 83,728 | 66,569 | $11.54M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 121,652 | 100,474 | $8.55M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 127,585 | 108,282 | $7.91M |
| 80053 | Comprehensive metabolic panel | 302,198 | 212,125 | $5.39M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 154,376 | 60,378 | $5.01M |
| J9271 | Injection, pembrolizumab, 1 mg | 3,828 | 2,743 | $4.31M |
| 70450 | Computed tomography, head or brain; without contrast material | 46,146 | 40,370 | $3.57M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 43,086 | 37,563 | $3.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 32,521 | 28,979 | $2.66M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 25,689 | 21,083 | $2.37M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27,886 | 24,893 | $2.27M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 375,774 | 261,206 | $2.24M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 54,065 | 26,521 | $2.24M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 33,332 | 22,876 | $2.20M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 21,369 | 12,339 | $1.96M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 36,036 | 29,506 | $1.90M |
| 80048 | Basic metabolic panel (calcium, ionized) | 90,921 | 59,816 | $1.85M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 84,075 | 34,934 | $1.84M |
| 84484 | 131,308 | 102,674 | $1.49M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 14,410 | 13,038 | $1.46M |
| 80047 | 47,492 | 42,181 | $1.32M | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 14,693 | 13,100 | $1.29M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 32,259 | 29,131 | $1.22M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 58,031 | 30,204 | $1.21M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 26,597 | 15,468 | $1.20M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 14,962 | 13,476 | $1.13M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5,700 | 5,249 | $1.12M |
| 83880 | 38,368 | 31,610 | $1.10M | |
| 77386 | 8,331 | 699 | $1.03M | |
| 93356 | 10,936 | 9,769 | $1.02M | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 16,851 | 12,741 | $1.01M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 35,199 | 16,820 | $1.01M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 24,876 | 21,397 | $998K |
| 93798 | 15,949 | 2,907 | $971K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 26,948 | 24,517 | $969K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 26,982 | 24,554 | $904K |
| P9016 | Red blood cells, leukocytes reduced, each unit | 2,863 | 1,910 | $875K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,836 | 1,141 | $858K |
| 84703 | 53,832 | 48,218 | $814K | |
| 97162 | 21,796 | 20,068 | $797K | |
| 84702 | 45,583 | 38,602 | $785K | |
| 93458 | 1,796 | 1,653 | $783K | |
| 99215 | Prolong outpt/office vis | 19,940 | 16,412 | $761K |
| G0378 | Hospital observation service, per hour | 44,538 | 36,754 | $755K |
| 97161 | 19,222 | 17,357 | $749K | |
| 82962 | 96,099 | 45,492 | $737K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 4,387 | 4,016 | $734K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 4,010 | 3,682 | $713K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 8,878 | 7,845 | $704K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22,723 | 19,392 | $702K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 12,484 | 9,863 | $690K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2,758 | 2,555 | $659K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 5,834 | 5,356 | $623K |
| 82077 | 28,981 | 22,630 | $619K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 3,129 | 2,877 | $584K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11,216 | 8,921 | $557K |
| 96367 | 10,305 | 7,106 | $551K | |
| 83690 | 93,899 | 78,769 | $545K | |
| J2505 | Injection, pegfilgrastim, 6 mg | 902 | 630 | $540K |
| 83735 | 106,760 | 68,169 | $521K | |
| 49083 | 3,540 | 1,581 | $521K | |
| 96415 | 5,963 | 4,553 | $509K | |
| 77412 | 4,863 | 591 | $504K | |
| 93975 | 10,823 | 9,906 | $497K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 10,589 | 9,744 | $491K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 13,052 | 11,811 | $484K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2,471 | 2,306 | $480K |
| 27447 | 282 | 250 | $475K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 40,990 | 36,049 | $469K |
| 72125 | Computed tomography, cervical spine; without contrast material | 14,952 | 13,290 | $469K |
| 93308 | 4,171 | 3,724 | $467K | |
| 76830 | Ultrasound, transvaginal | 11,265 | 10,351 | $460K |
| 64493 | 1,881 | 1,664 | $459K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 6,650 | 6,082 | $458K |
| 86850 | 21,995 | 18,299 | $446K | |
| 64483 | 2,457 | 2,256 | $445K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 13,721 | 12,280 | $431K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2,608 | 2,466 | $417K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 13,400 | 12,511 | $413K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 14,896 | 13,750 | $401K |
| 97597 | 8,915 | 5,967 | $400K | |
| 29580 | 7,146 | 1,983 | $395K | |
| 93321 | 4,249 | 3,726 | $389K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 5,350 | 4,975 | $385K |
| 64494 | 2,455 | 1,525 | $380K | |
| 19083 | 1,075 | 973 | $371K | |
| 76642 | 9,660 | 7,518 | $369K | |
| 71046 | Radiologic examination, chest; 2 views | 45,900 | 41,218 | $364K |
| 12001 | 3,917 | 3,573 | $360K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 9,512 | 8,940 | $357K |
| 43235 | 1,986 | 1,832 | $356K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,032 | 830 | $354K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1,412 | 1,208 | $352K |
| 70496 | 4,019 | 3,608 | $351K | |
| 81025 | 32,435 | 29,058 | $348K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3,412 | 3,151 | $336K |
| 70498 | 4,277 | 3,855 | $329K | |
| 84443 | Thyroid stimulating hormone (TSH) | 27,691 | 23,756 | $328K |
| 85610 | 66,668 | 45,272 | $315K | |
| 10060 | 3,436 | 3,112 | $313K | |
| 81003 | 65,393 | 58,003 | $305K | |
| 82803 | 16,251 | 13,748 | $304K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 2,856 | 1,503 | $301K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 306 | 265 | $296K |
| 97116 | 20,254 | 10,690 | $296K | |
| 93971 | 9,536 | 8,643 | $288K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 4,311 | 3,829 | $286K |
| 64636 | 1,371 | 712 | $286K | |
| 93351 | 2,383 | 2,135 | $283K | |
| J2350 | Injection, ocrelizumab, 1 mg | 98 | 89 | $273K |
| 90715 | 11,037 | 10,043 | $273K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | 2,971 | 1,361 | $272K |
| 97165 | 8,289 | 7,266 | $271K | |
| 96417 | 6,177 | 3,737 | $270K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 53,767 | 39,548 | $269K |
| 90686 | 7,467 | 6,698 | $266K | |
| 62323 | 2,049 | 1,922 | $261K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 639 | 416 | $259K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6,967 | 2,988 | $257K |
| 12011 | 2,808 | 2,563 | $256K | |
| 64635 | 884 | 758 | $249K | |
| 81001 | 69,365 | 60,896 | $248K | |
| 83605 | 25,899 | 20,759 | $243K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 4,334 | 3,980 | $239K |
| 71250 | 6,560 | 6,077 | $236K | |
| 70486 | 6,702 | 6,156 | $236K | |
| 85027 | 50,908 | 31,966 | $231K | |
| 47563 | 240 | 202 | $231K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 16,803 | 7,711 | $227K |
| 70491 | 2,886 | 2,658 | $223K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 2,952 | 2,590 | $223K |
| 82565 | 11,496 | 10,465 | $222K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 10,028 | 9,092 | $220K |
| 83036 | Hemoglobin; glycosylated (A1C) | 21,781 | 19,089 | $219K |
| 20610 | 2,314 | 1,962 | $218K | |
| 0240U | 6,544 | 6,044 | $217K | |
| 81513 | 2,734 | 2,428 | $215K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5,369 | 4,939 | $214K |
| 80061 | Lipid panel | 18,237 | 16,078 | $213K |
| 85379 | 24,974 | 22,021 | $203K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 12,196 | 11,343 | $202K |
| 52356 | 211 | 195 | $202K | |
| 84145 | 10,972 | 9,153 | $200K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 83,722 | 50,490 | $200K |
| 12002 | 2,159 | 1,939 | $196K | |
| 86900 | 23,795 | 19,763 | $194K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2,431 | 2,153 | $192K |
| 72141 | 2,789 | 2,550 | $190K | |
| 96368 | 4,015 | 2,741 | $189K | |
| 95886 | 3,552 | 3,339 | $189K | |
| 95811 | 1,426 | 1,331 | $188K | |
| 97535 | Self-care/home management training, each 15 minutes | 15,312 | 9,259 | $188K |
| 94729 | 7,293 | 6,695 | $186K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1,014 | 431 | $183K |
| 96416 | 1,607 | 911 | $180K | |
| J9312 | Injection, rituximab, 10 mg | 414 | 161 | $179K |
| 82728 | 17,394 | 15,020 | $178K | |
| 93325 | 4,504 | 3,939 | $177K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 99,073 | 76,615 | $177K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | 137 | 113 | $177K |
| 93017 | 4,901 | 4,461 | $177K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 7,917 | 7,165 | $175K |
| 78582 | 1,155 | 1,070 | $175K | |
| 36430 | 2,470 | 1,412 | $174K | |
| 94060 | 6,200 | 5,673 | $172K | |
| 93970 | 3,855 | 3,545 | $171K | |
| 97166 | 5,827 | 5,257 | $170K | |
| J9035 | Injection, bevacizumab, 10 mg | 465 | 205 | $159K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,971 | 1,709 | $158K |
| 76770 | 3,255 | 3,022 | $158K | |
| 87040 | 12,941 | 10,046 | $158K | |
| 73221 | 2,194 | 1,906 | $157K | |
| 29125 | 3,224 | 2,911 | $155K | |
| 29581 | 2,939 | 746 | $154K | |
| J9299 | Injection, nivolumab, 1 mg | 253 | 99 | $152K |
| 47562 | 167 | 148 | $152K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1,000 | 871 | $151K |
| J0897 | Injection, denosumab, 1 mg | 1,796 | 1,643 | $151K |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 179 | 124 | $150K |
| 80143 | 12,862 | 10,269 | $150K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8,172 | 7,088 | $148K |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 515 | 423 | $148K |
| 80179 | 12,594 | 10,075 | $146K | |
| 87077 | 11,933 | 10,743 | $142K | |
| 77066 | Tomosynthesis, mammo | 5,583 | 5,012 | $142K |
| 77336 | 4,760 | 2,177 | $140K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 21,699 | 19,135 | $140K |
| J1756 | Injection, iron sucrose, 1 mg | 16,496 | 6,870 | $138K |
| 87481 | 2,678 | 2,389 | $138K | |
| 87210 | 15,928 | 14,698 | $135K | |
| 86832 | 1,672 | 1,449 | $134K | |
| 74174 | 1,596 | 1,423 | $132K | |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 297 | 104 | $132K |
| Q3014 | Telehealth originating site facility fee | 8,971 | 7,388 | $130K |
| 74183 | 1,313 | 1,209 | $128K | |
| 97113 | 2,167 | 845 | $127K | |
| J9022 | Injection, atezolizumab, 10 mg | 117 | 83 | $122K |
| 87641 | 3,325 | 2,944 | $122K | |
| 94660 | 2,515 | 1,167 | $122K | |
| 74170 | 1,574 | 1,453 | $120K | |
| 80076 | 13,674 | 12,240 | $120K | |
| 85730 | 24,862 | 20,059 | $118K | |
| 83970 | 4,357 | 3,950 | $118K | |
| 77065 | Tomosynthesis, mammo | 5,294 | 4,516 | $117K |
| 72100 | 14,423 | 13,240 | $116K | |
| 86833 | 1,743 | 1,514 | $113K | |
| J1453 | Injection, fosaprepitant, 1 mg | 4,326 | 2,776 | $111K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3,260 | 2,817 | $107K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 249 | 163 | $107K |
| 76801 | 9,206 | 7,879 | $107K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | 339 | 322 | $106K |
| 36561 | 249 | 232 | $106K | |
| 89051 | 4,392 | 2,592 | $106K | |
| 87186 | 12,862 | 11,565 | $106K | |
| 93454 | 284 | 253 | $105K | |
| 94618 | 3,223 | 2,937 | $100K | |
| 72197 | 956 | 855 | $99K | |
| 76536 | 2,169 | 2,047 | $98K | |
| 86480 | 1,765 | 1,584 | $98K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 4,283 | 3,711 | $97K |
| 83550 | 15,858 | 14,063 | $96K | |
| 97035 | 7,638 | 3,668 | $96K | |
| 82330 | 5,826 | 4,308 | $93K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1,892 | 979 | $92K |
| 52332 | 376 | 342 | $92K | |
| 82607 | 8,414 | 7,499 | $91K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 164,447 | 131,558 | $91K |
| 87070 | 7,339 | 5,372 | $90K | |
| 86803 | 6,419 | 5,788 | $88K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 1,014 | 477 | $85K |
| 77080 | 1,872 | 1,735 | $84K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 2,251 | 2,006 | $84K |
| 83615 | 20,477 | 15,894 | $82K | |
| 71271 | 1,578 | 1,405 | $81K | |
| 77062 | 4,572 | 4,156 | $80K | |
| 0399T | 3,727 | 3,381 | $80K | |
| 93451 | 257 | 234 | $79K | |
| 19318 | 35 | 26 | $77K | |
| 29130 | 1,738 | 1,594 | $77K | |
| 64484 | 546 | 459 | $77K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 243 | 217 | $76K |
| 92523 | 827 | 736 | $76K | |
| 83540 | 16,425 | 14,539 | $76K | |
| 84132 | 10,094 | 8,122 | $73K | |
| 82105 | 4,044 | 3,609 | $71K | |
| 82746 | 7,158 | 6,327 | $71K | |
| 87081 | 3,511 | 3,304 | $70K | |
| 80197 | 7,051 | 3,839 | $69K | |
| 92610 | 2,148 | 1,884 | $69K | |
| 97163 | 2,129 | 2,003 | $69K | |
| 93307 | 613 | 563 | $68K | |
| 95819 | 1,022 | 910 | $67K | |
| 87340 | 7,970 | 7,013 | $67K | |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 121 | 51 | $65K |
| 73562 | 14,785 | 12,451 | $65K | |
| 86140 | 14,042 | 10,588 | $64K | |
| 87563 | 2,586 | 2,305 | $64K | |
| 74018 | 6,203 | 5,221 | $64K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 978 | 909 | $63K |
| 76870 | 1,892 | 1,710 | $62K | |
| 19081 | 197 | 181 | $60K | |
| 58558 | 93 | 78 | $58K | |
| 82784 | 4,224 | 3,650 | $58K | |
| 77002 | 2,365 | 2,012 | $57K | |
| 36000 | 21,441 | 19,422 | $57K | |
| 77300 | 1,342 | 1,137 | $56K | |
| 58661 | 69 | 50 | $56K | |
| 86901 | 23,778 | 19,759 | $56K | |
| 58100 | 295 | 264 | $55K | |
| 99201 | 958 | 865 | $55K | |
| 72040 | 3,404 | 3,163 | $55K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3,721 | 2,803 | $55K |
| 77061 | 3,701 | 3,241 | $54K | |
| 87522 | Neg quan hep c or qual rna | 1,345 | 1,174 | $54K |
| 73030 | 12,127 | 10,705 | $53K | |
| 94726 | 6,600 | 6,047 | $53K | |
| 72110 | 2,318 | 2,185 | $52K | |
| 82550 | 10,121 | 8,038 | $52K | |
| 10160 | 536 | 493 | $52K | |
| 82570 | 9,204 | 8,204 | $51K | |
| 27130 | 29 | 26 | $51K | |
| 77334 | 2,151 | 1,447 | $50K | |
| 76882 | 1,213 | 1,080 | $50K | |
| 87529 | 761 | 719 | $50K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 9,399 | 7,411 | $49K |
| 77301 | 303 | 258 | $48K | |
| 90651 | 840 | 805 | $48K | |
| 87088 | 6,806 | 6,208 | $48K | |
| 77290 | 677 | 610 | $47K | |
| H2012 | Behavioral health day treatment, per hour | 609 | 91 | $46K |
| 71045 | Radiologic examination, chest; single view | 96,403 | 81,928 | $46K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 670 | 350 | $46K |
| 97016 | 2,820 | 1,158 | $46K | |
| 85014 | 18,728 | 16,324 | $45K | |
| 86592 | 7,805 | 7,062 | $45K | |
| 90670 | 1,037 | 1,012 | $45K | |
| 96112 | 158 | 142 | $45K | |
| 86706 | 4,794 | 4,205 | $45K | |
| 73130 | 11,617 | 9,891 | $44K | |
| 27096 | 191 | 172 | $44K | |
| 64615 | 463 | 440 | $44K | |
| 29515 | 1,051 | 933 | $43K | |
| 97803 | 2,090 | 1,711 | $43K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1,366 | 972 | $43K |
| 95913 | 688 | 654 | $41K | |
| 73630 | 11,614 | 10,173 | $41K | |
| 84100 | 13,021 | 8,061 | $40K | |
| 92526 | 1,781 | 997 | $40K | |
| 95910 | 615 | 583 | $40K | |
| 84439 | 4,909 | 4,243 | $40K | |
| 86704 | 3,668 | 3,185 | $40K | |
| 82378 | 2,972 | 2,394 | $39K | |
| 90680 | 1,350 | 1,262 | $39K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 7,225 | 6,158 | $38K |
| 76937 | 4,612 | 4,006 | $38K | |
| 84112 | 427 | 375 | $37K | |
| 87497 | 1,392 | 878 | $36K | |
| 84153 | 2,897 | 2,527 | $36K | |
| 90648 | 1,637 | 1,543 | $36K | |
| 82247 | 800 | 524 | $36K | |
| 51705 | 536 | 483 | $35K | |
| 74230 | 763 | 703 | $35K | |
| 74178 | 479 | 438 | $35K | |
| 87507 | 102 | 93 | $35K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 87 | 77 | $35K |
| 94010 | 1,740 | 1,610 | $34K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 93 | 39 | $34K |
| 86334 | 2,779 | 2,387 | $33K | |
| 86923 | 3,201 | 2,237 | $33K | |
| 73502 | 6,609 | 6,021 | $33K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 1,757 | 501 | $33K |
| 87075 | 4,979 | 3,377 | $32K | |
| 93653 | 14 | 12 | $32K | |
| 75561 | 314 | 293 | $32K | |
| 72050 | 1,261 | 1,175 | $31K | |
| 29827 | 27 | 27 | $31K | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | 1,125 | 963 | $31K |
| 73700 | 839 | 747 | $31K | |
| 80164 | 2,803 | 2,288 | $31K | |
| 87799 | 1,093 | 740 | $31K | |
| 63650 | 25 | 12 | $30K | |
| 73610 | 9,854 | 8,849 | $30K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 503 | 456 | $29K |
| 82075 | 1,040 | 882 | $29K | |
| 82140 | 2,765 | 1,973 | $29K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 101 | 57 | $29K |
| 82043 | 3,651 | 3,331 | $29K | |
| 80074 | 678 | 589 | $28K | |
| 87205 | 9,232 | 6,834 | $28K | |
| J2357 | Injection, omalizumab, 5 mg | 138 | 51 | $28K |
| 90732 | 1,256 | 1,061 | $27K | |
| 96523 | 1,351 | 1,154 | $27K | |
| 43264 | 42 | 37 | $27K | |
| 87493 | 999 | 898 | $27K | |
| 86038 | 2,422 | 2,142 | $27K | |
| 92611 | 554 | 523 | $26K | |
| 62321 | 214 | 198 | $26K | |
| 93880 | 745 | 656 | $26K | |
| 90746 | 1,311 | 1,122 | $26K | |
| 95874 | 990 | 927 | $26K | |
| 97012 | 1,422 | 713 | $26K | |
| 90677 | 2,352 | 1,977 | $25K | |
| 84481 | 2,137 | 1,849 | $25K | |
| 86762 | 2,089 | 1,872 | $25K | |
| 84550 | 6,760 | 5,416 | $25K | |
| 72146 | 411 | 368 | $25K | |
| 72156 | 248 | 223 | $24K | |
| 72158 | 315 | 294 | $24K | |
| 83520 | 1,439 | 1,252 | $24K | |
| 36592 | 2,273 | 1,813 | $24K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 14 | 12 | $23K |
| 80177 | 1,926 | 1,607 | $23K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 87,378 | 63,586 | $23K |
| 84165 | 3,789 | 3,269 | $23K | |
| 93312 | 277 | 247 | $23K | |
| J9306 | Injection, pertuzumab, 1 mg | 33 | 24 | $23K |
| 85046 | 6,207 | 4,957 | $22K | |
| 90674 | 630 | 555 | $22K | |
| 85652 | 10,856 | 9,179 | $22K | |
| 87517 | 571 | 516 | $22K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 453 | 296 | $22K |
| 78306 | 285 | 280 | $22K | |
| 86300 | 1,899 | 1,590 | $21K | |
| 84156 | 6,686 | 5,786 | $21K | |
| 72131 | 622 | 557 | $21K | |
| 86787 | 2,689 | 2,408 | $21K | |
| 73110 | 6,188 | 5,542 | $21K | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 44 | 25 | $21K |
| 88307 | 3,517 | 3,021 | $21K | |
| 20611 | 139 | 112 | $20K | |
| 59025 | Fetal non-stress test | 273 | 254 | $20K |
| 82375 | 774 | 671 | $19K | |
| 86235 | 151 | 138 | $19K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | 171 | 126 | $18K |
| 72070 | 3,445 | 3,163 | $18K | |
| 97167 | 588 | 545 | $18K | |
| 91200 | 2,159 | 1,895 | $17K | |
| 90716 | 479 | 458 | $17K | |
| 88185 | 1,119 | 957 | $17K | |
| 86301 | 1,103 | 864 | $17K | |
| 93320 | 196 | 168 | $17K | |
| 82805 | 451 | 377 | $17K | |
| 73140 | 4,282 | 3,880 | $17K | |
| 93922 | 585 | 550 | $17K | |
| 83516 | 980 | 861 | $17K | |
| 77001 | 1,265 | 1,136 | $17K | |
| 12013 | 189 | 172 | $16K | |
| 85347 | 2,223 | 1,962 | $16K | |
| 90633 | 870 | 820 | $16K | |
| G0277 | Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | 114 | 13 | $16K |
| 78830 | 113 | 95 | $16K | |
| 93925 | 485 | 448 | $16K | |
| 77387 | 1,784 | 204 | $15K | |
| 36591 | 2,351 | 1,887 | $15K | |
| 84146 | 825 | 747 | $15K | |
| 83655 | 949 | 898 | $15K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2,259 | 2,040 | $15K |
| 83521 | 1,243 | 1,054 | $15K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 313 | 277 | $14K |
| 96402 | 3,028 | 2,676 | $14K | |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 680 | 227 | $14K |
| V5266 | Battery for use in hearing device | 1,314 | 1,163 | $14K |
| 87902 | 67 | 51 | $13K | |
| 82670 | 499 | 454 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1,155 | 1,040 | $13K |
| 38222 | 69 | 64 | $13K | |
| 92557 | 365 | 262 | $13K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 412 | 381 | $13K |
| 83883 | 932 | 825 | $12K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 310 | 284 | $12K |
| J2997 | Injection, alteplase recombinant, 1 mg | 509 | 425 | $12K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 68 | 56 | $12K |
| 73080 | 3,618 | 3,298 | $12K | |
| 77338 | 289 | 245 | $12K | |
| 76775 | 413 | 383 | $12K | |
| 64721 | 57 | 50 | $12K | |
| 29105 | 134 | 120 | $11K | |
| 94644 | 1,999 | 1,701 | $11K | |
| 87102 | 1,460 | 1,257 | $11K | |
| 82950 | 1,468 | 1,386 | $11K | |
| 88360 | 1,501 | 1,300 | $11K | |
| 83020 | 1,642 | 1,450 | $11K | |
| 75716 | 31 | 29 | $11K | |
| 94621 | 243 | 221 | $11K | |
| 97802 | 550 | 443 | $11K | |
| 75565 | 194 | 175 | $11K | |
| 97018 | 947 | 527 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 21,830 | 19,624 | $11K |
| 87015 | 2,408 | 1,701 | $10K | |
| 87147 | 1,888 | 1,649 | $10K | |
| 58301 | 74 | 69 | $9K | |
| J9041 | Injection, bortezomib, 0.1 mg | 60 | 12 | $9K |
| 90739 | 447 | 416 | $9K | |
| 73560 | 1,749 | 1,426 | $9K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 173 | 163 | $9K |
| J9171 | Injection, docetaxel, 1 mg | 190 | 137 | $9K |
| 90750 | 1,146 | 996 | $9K | |
| 87449 | 974 | 719 | $9K | |
| 83001 | 483 | 446 | $9K | |
| 90723 | 1,606 | 1,512 | $9K | |
| 86708 | 804 | 699 | $9K | |
| 86147 | 476 | 419 | $9K | |
| 43249 | 70 | 54 | $9K | |
| 93296 | 1,779 | 1,654 | $9K | |
| J3489 | Injection, zoledronic acid, 1 mg | 1,020 | 888 | $8K |
| 84403 | 402 | 364 | $8K | |
| 90656 | 1,015 | 979 | $8K | |
| 64490 | 39 | 37 | $8K | |
| 88184 | 1,126 | 957 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 206 | 176 | $8K |
| 36821 | 14 | 12 | $8K | |
| 97542 | 524 | 482 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 136,015 | 98,586 | $8K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 18 | 12 | $8K |
| 36415 | Collection of venous blood by venipuncture | 73,539 | 45,914 | $8K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 225 | 193 | $8K |
| 58300 | 146 | 125 | $8K | |
| 86160 | 385 | 356 | $8K | |
| J9173 | Injection, durvalumab, 10 mg | 39 | 12 | $8K |
| 82103 | 571 | 499 | $8K | |
| 85018 | 3,412 | 2,429 | $7K | |
| 62369 | 151 | 143 | $7K | |
| 90662 | 708 | 625 | $7K | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 4,549 | 1,821 | $7K |
| 73090 | 3,196 | 2,905 | $7K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 86 | 65 | $7K |
| J2785 | Injection, regadenoson, 0.1 mg | 3,881 | 3,538 | $7K |
| J9070 | Cyclophosphamide, 100 mg | 318 | 78 | $7K |
| 64644 | 158 | 144 | $7K | |
| 82150 | 652 | 518 | $7K | |
| 82010 | 1,065 | 851 | $7K | |
| 73590 | 4,558 | 3,989 | $7K | |
| 93299 | 138 | 131 | $7K | |
| 76942 | 1,628 | 1,476 | $7K | |
| 86780 | 655 | 585 | $7K | |
| 95912 | 124 | 120 | $6K | |
| 97605 | 112 | 37 | $6K | |
| 41800 | 83 | 75 | $6K | |
| 86308 | 750 | 685 | $6K | |
| 88344 | 1,463 | 1,270 | $6K | |
| 76376 | 5,362 | 4,746 | $6K | |
| 85461 | 744 | 689 | $6K | |
| 80185 | 538 | 395 | $6K | |
| 10005 | 39 | 39 | $6K | |
| 90734 | 163 | 157 | $6K | |
| 86920 | 1,173 | 763 | $6K | |
| 71101 | 3,263 | 2,990 | $6K | |
| 77049 | 48 | 41 | $6K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 1,133 | 996 | $5K |
| 70487 | 58 | 54 | $5K | |
| 73660 | 1,308 | 1,191 | $5K | |
| 74022 | 3,347 | 3,008 | $5K | |
| 78580 | 31 | 27 | $5K | |
| 86870 | 584 | 426 | $5K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 156 | 139 | $5K |
| 74181 | 45 | 41 | $5K | |
| 82271 | 1,231 | 1,115 | $5K | |
| 96401 | 1,526 | 621 | $5K | |
| 80329 | 1,176 | 1,021 | $5K | |
| 78264 | 59 | 53 | $5K | |
| 64643 | 68 | 63 | $5K | |
| 86304 | 453 | 338 | $5K | |
| 86431 | 894 | 804 | $5K | |
| 82248 | 1,140 | 949 | $5K | |
| C1874 | Stent, coated/covered, with delivery system | 713 | 644 | $5K |
| 85613 | 453 | 413 | $5K | |
| 87116 | 601 | 493 | $5K | |
| 72170 | 2,264 | 2,067 | $5K | |
| 83037 | 961 | 886 | $5K | |
| 97022 | 254 | 101 | $4K | |
| 93926 | 180 | 164 | $4K | |
| 86200 | 408 | 360 | $4K | |
| 85576 | 109 | 93 | $4K | |
| 96409 | 1,623 | 955 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 74,859 | 62,752 | $4K |
| 87899 | 234 | 186 | $4K | |
| 74019 | 800 | 745 | $4K | |
| 73060 | 1,993 | 1,806 | $4K | |
| 73552 | 2,181 | 1,907 | $4K | |
| 82104 | 329 | 286 | $4K | |
| 95909 | 49 | 49 | $4K | |
| 84295 | 829 | 766 | $4K | |
| 87045 | 423 | 397 | $4K | |
| 88142 | 192 | 164 | $4K | |
| 86225 | 335 | 304 | $4K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 25 | 15 | $4K |
| 31720 | 260 | 248 | $4K | |
| 88237 | 83 | 76 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 62,415 | 49,487 | $3K |
| 82977 | 557 | 482 | $3K | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 179 | 111 | $3K |
| G0379 | Direct admission of patient for hospital observation care | 808 | 658 | $3K |
| 31231 | 71 | 66 | $3K | |
| 84425 | 190 | 175 | $3K | |
| 73564 | 1,195 | 1,036 | $3K | |
| 64491 | 16 | 12 | $3K | |
| 31624 | 25 | 24 | $3K | |
| 87521 | Neg quan hep c or qual rna | 115 | 103 | $3K |
| 77280 | 41 | 38 | $3K | |
| 90700 | 458 | 440 | $3K | |
| 83010 | 407 | 351 | $3K | |
| 87427 | 341 | 319 | $3K | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 1,606 | 603 | $3K |
| 94625 | 395 | 109 | $3K | |
| 36902 | 14 | 12 | $3K | |
| 82947 | 830 | 758 | $3K | |
| 84300 | 936 | 773 | $3K | |
| 86665 | 133 | 114 | $3K | |
| 75574 | 31 | 28 | $3K | |
| 86015 | 275 | 242 | $3K | |
| 80050 | General health panel | 2,386 | 2,163 | $3K |
| 72120 | 132 | 125 | $3K | |
| 82533 | 201 | 178 | $3K | |
| 88112 | 727 | 624 | $3K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 9,427 | 7,706 | $3K |
| C1729 | Catheter, drainage | 2,984 | 1,916 | $3K |
| 90707 | 458 | 438 | $3K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 66 | 62 | $3K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 84 | 80 | $3K |
| 72082 | 76 | 75 | $3K | |
| 51702 | 779 | 648 | $3K | |
| 85390 | 455 | 414 | $3K | |
| 83013 | 42 | 41 | $3K | |
| 77012 | 271 | 232 | $3K | |
| J9395 | Injection, fulvestrant, 25 mg | 40 | 36 | $3K |
| 64495 | 20 | 12 | $3K | |
| 72157 | 27 | 24 | $2K | |
| Q0114 | Fern test | 346 | 297 | $2K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 9,183 | 8,169 | $2K |
| 86146 | 123 | 121 | $2K | |
| 86381 | 261 | 230 | $2K | |
| 77295 | 13 | 12 | $2K | |
| 29826 | 13 | 13 | $2K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 17 | 13 | $2K |
| 86922 | 647 | 404 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 30,458 | 20,861 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 78,234 | 56,002 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 34,102 | 26,070 | $2K |
| 81002 | 94 | 93 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | 10,742 | 5,074 | $2K |
| 36593 | 40 | 37 | $2K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 625 | 187 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 1,390 | 1,162 | $2K |
| 88304 | 4,053 | 3,640 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | 72,523 | 30,702 | $2K |
| 86364 | 192 | 178 | $2K | |
| 57454 | 14 | 12 | $2K | |
| 36589 | 29 | 25 | $2K | |
| C1769 | Guide wire | 14,849 | 12,984 | $2K |
| 87206 | 510 | 428 | $2K | |
| 86705 | 250 | 215 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | 35,740 | 13,836 | $2K |
| 96376 | 31,852 | 18,546 | $2K | |
| 95700 | 29 | 27 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 58,618 | 45,955 | $2K |
| 87350 | 155 | 139 | $2K | |
| 87176 | 379 | 328 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 3,805 | 3,372 | $2K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 2,131 | 1,503 | $2K |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 25 | 25 | $2K |
| 90696 | 72 | 65 | $2K | |
| 36600 | 415 | 367 | $2K | |
| 86709 | 156 | 144 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 684 | 610 | $1K |
| 80175 | 95 | 87 | $1K | |
| 70549 | 13 | 12 | $1K | |
| 87076 | 179 | 143 | $1K | |
| 78227 | 13 | 13 | $1K | |
| 84157 | 443 | 358 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19,822 | 13,759 | $1K |
| 97129 | 138 | 79 | $1K | |
| 82951 | 24 | 24 | $1K | |
| 86769 | 29 | 27 | $1K | |
| 87536 | 13 | 13 | $1K | |
| 51798 | 2,804 | 2,448 | $1K | |
| A4648 | Tissue marker, implantable, any type, each | 2,097 | 1,893 | $1K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 4,550 | 4,040 | $1K |
| 84134 | 201 | 167 | $1K | |
| 72220 | 360 | 330 | $1K | |
| 70490 | 36 | 36 | $1K | |
| C1760 | Closure device, vascular (implantable/insertable) | 1,217 | 1,057 | $1K |
| 92567 | 35 | 25 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 41 | 37 | $1K |
| 72193 | 14 | 12 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 40,908 | 35,804 | $1K |
| 73120 | 219 | 136 | $1K | |
| 83498 | 54 | 49 | $1K | |
| 95012 | 167 | 150 | $1K | |
| 73100 | 334 | 204 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 17,287 | 10,507 | $1K |
| 87046 | 488 | 455 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 9,477 | 8,372 | $1K |
| 82272 | 303 | 263 | $1K | |
| 99245 | 13 | 13 | $1K | |
| 84155 | 315 | 268 | $1K | |
| 82945 | 227 | 195 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 36,914 | 14,924 | $1K |
| 92083 | 387 | 347 | $1K | |
| 93976 | 29 | 24 | $1K | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 4,095 | 2,096 | $990.82 |
| 82365 | 44 | 42 | $986.92 | |
| 93282 | 173 | 162 | $969.57 | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | 27 | 27 | $957.79 |
| 73620 | 223 | 188 | $954.19 | |
| 88342 | 2,893 | 2,634 | $952.22 | |
| 74160 | 12 | 12 | $948.44 | |
| 90678 | 66 | 59 | $935.71 | |
| 82668 | 87 | 65 | $907.94 | |
| 82390 | 102 | 92 | $902.70 | |
| 85732 | 149 | 140 | $897.43 | |
| J2704 | Injection, propofol, 10 mg | 57,944 | 37,640 | $879.90 |
| 56405 | 13 | 12 | $862.60 | |
| 90480 | 26 | 25 | $857.85 | |
| 90381 | 18 | 18 | $852.18 | |
| 87480 | 42 | 39 | $843.31 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 32,508 | 25,050 | $842.06 |
| J9190 | Injection, fluorouracil, 500 mg | 3,761 | 1,234 | $839.73 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 6,428 | 5,056 | $829.48 |
| 94150 | 1,378 | 712 | $829.37 | |
| 95911 | 26 | 26 | $827.80 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 391 | 360 | $821.95 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 4,311 | 3,796 | $817.39 |
| J1815 | Injection, insulin, per 5 units | 41,644 | 12,923 | $812.88 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 12 | 12 | $809.21 |
| 87510 | 42 | 39 | $781.15 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 26,062 | 21,278 | $767.59 |
| 0031A | 22 | 21 | $754.05 | |
| 77399 | 54 | 38 | $750.91 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 33,617 | 20,921 | $746.93 |
| 82627 | 12 | 12 | $744.75 | |
| 87154 | 87 | 78 | $730.95 | |
| 86707 | 70 | 65 | $723.92 | |
| J9206 | Injection, irinotecan, 20 mg | 98 | 49 | $723.44 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 2,058 | 1,845 | $717.28 |
| 85049 | 24 | 16 | $710.79 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 3,157 | 1,824 | $699.13 |
| 70360 | 337 | 310 | $691.44 | |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) | 63 | 56 | $667.08 |
| 99205 | Prolong outpt/office vis | 15 | 12 | $643.91 |
| 83930 | 144 | 118 | $639.55 | |
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | 29 | 22 | $632.28 |
| 73521 | 73 | 71 | $628.76 | |
| 90710 | 94 | 81 | $626.28 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 24 | 18 | $601.48 |
| 86593 | 155 | 146 | $589.32 | |
| Q0247 | Injection, sotrovimab, 500 mg | 22 | 17 | $579.04 |
| 80178 | 111 | 94 | $578.08 | |
| 80320 | 4,203 | 3,459 | $568.48 | |
| 95712 | 15 | 13 | $554.61 | |
| 96381 | 56 | 52 | $551.21 | |
| 96411 | 3,440 | 2,236 | $544.89 | |
| 85384 | 59 | 49 | $539.21 | |
| 88173 | 1,012 | 904 | $530.56 | |
| G0008 | Administration of influenza virus vaccine | 1,214 | 1,067 | $522.66 |
| 97130 | 24 | 13 | $506.58 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 18 | 14 | $493.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 40,979 | 30,787 | $489.76 |
| J0690 | Injection, cefazolin sodium, 500 mg | 21,500 | 16,526 | $482.16 |
| 74220 | 28 | 25 | $479.03 | |
| 99443 | 33 | 28 | $469.18 | |
| 95992 | 23 | 12 | $457.48 | |
| 90380 | 35 | 33 | $426.09 | |
| 86039 | 40 | 37 | $383.25 | |
| 88271 | 13 | 12 | $375.24 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2,329 | 2,194 | $367.19 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 756 | 646 | $363.43 |
| 36410 | 17 | 16 | $362.66 | |
| 92133 | 410 | 365 | $349.05 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 1,775 | 999 | $346.17 |
| 73600 | 26 | 24 | $340.07 | |
| 73070 | 58 | 56 | $338.94 | |
| 98966 | 20 | 12 | $338.85 | |
| 84166 | 27 | 25 | $337.20 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 16 | 13 | $322.76 |
| 86361 | 12 | 12 | $316.82 | |
| 72072 | 136 | 123 | $309.85 | |
| 83789 | 16 | 13 | $300.33 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 6,756 | 1,809 | $300.05 |
| 76819 | Fetal biophysical profile; without non-stress testing | 14 | 13 | $297.94 |
| A9585 | Injection, gadobutrol, 0.1 ml | 13,104 | 11,741 | $291.51 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 10,959 | 7,767 | $285.59 |
| 84450 | 55 | 53 | $272.13 | |
| 0124A | 12 | 12 | $270.94 | |
| 86644 | 17 | 12 | $266.94 | |
| 88313 | 1,072 | 967 | $258.34 | |
| 36247 | 19 | 12 | $242.27 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 3,504 | 3,098 | $237.83 |
| 36416 | 8,907 | 4,172 | $227.56 | |
| A4565 | Slings | 4,695 | 4,350 | $223.94 |
| 88333 | 463 | 399 | $212.16 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 94 | 79 | $205.41 |
| C9113 | Injection, pantoprazole sodium, per vial | 9,715 | 5,239 | $205.02 |
| 80202 | 21 | 13 | $186.91 | |
| 94727 | 70 | 63 | $186.05 | |
| 69200 | 14 | 12 | $180.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 1,327 | 1,016 | $164.36 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 4,378 | 3,132 | $163.58 |
| C1781 | Mesh (implantable) | 1,045 | 948 | $154.63 |
| 81050 | 46 | 38 | $153.63 | |
| A4212 | Non-coring needle or stylet with or without catheter | 13,180 | 6,268 | $149.38 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 29,021 | 13,769 | $147.27 |
| 86902 | 18 | 13 | $141.77 | |
| 87807 | 13 | 13 | $141.49 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 3,377 | 3,063 | $140.12 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 129 | 102 | $133.93 |
| A6248 | Hydrogel dressing, wound filler, gel, per fluid ounce | 925 | 646 | $132.72 |
| 73523 | 12 | 12 | $132.40 | |
| 71100 | 17 | 12 | $123.03 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 24 | 24 | $116.09 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 4,744 | 4,098 | $115.19 |
| 83921 | 13 | 12 | $111.35 | |
| 82232 | 14 | 13 | $110.19 | |
| 80162 | 16 | 12 | $109.76 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 2,171 | 1,975 | $108.84 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 955 | 565 | $106.36 |
| A9270 | Non-covered item or service | 41,995 | 3,152 | $101.90 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 2,082 | 1,547 | $96.95 |
| 99152 | 3,389 | 3,068 | $93.14 | |
| 82042 | 15 | 12 | $92.97 | |
| 86880 | 18 | 17 | $90.80 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 272 | 247 | $89.74 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 37,203 | 13,928 | $86.35 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 22,773 | 15,321 | $77.26 |
| 85670 | 414 | 380 | $75.29 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 4,658 | 4,031 | $73.88 |
| 97810 | 30 | 30 | $72.87 | |
| 88302 | 489 | 412 | $71.72 | |
| 88312 | 1,272 | 1,094 | $71.07 | |
| 93041 | 640 | 592 | $70.76 | |
| 90713 | 14 | 14 | $66.25 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 6,753 | 5,068 | $65.45 |
| 70355 | 16 | 12 | $57.65 | |
| J2060 | Injection, lorazepam, 2 mg | 15,482 | 11,254 | $55.09 |
| J1940 | Injection, furosemide, up to 20 mg | 9,189 | 4,405 | $54.94 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 2,630 | 2,301 | $54.42 |
| 93280 | 25 | 25 | $49.53 | |
| 83050 | 14 | 12 | $46.55 | |
| J7999 | Compounded drug, not otherwise classified | 2,313 | 1,860 | $43.40 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 4,621 | 4,227 | $38.30 |
| 73000 | 12 | 12 | $37.48 | |
| 88311 | 610 | 552 | $36.52 | |
| 97811 | 29 | 29 | $33.59 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 4,212 | 1,350 | $30.27 |
| 92060 | 52 | 48 | $26.93 | |
| J3480 | Injection, potassium chloride, per 2 meq | 11,902 | 6,509 | $25.65 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 7,105 | 1,841 | $24.11 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 689 | 597 | $22.97 |
| 93225 | 15 | 12 | $22.38 | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 787 | 409 | $21.52 |
| C1758 | Catheter, ureteral | 2,299 | 2,042 | $18.57 |
| 99153 | Mod sedat endo service >5yrs | 1,253 | 1,141 | $18.49 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 713 | 625 | $15.46 |
| J1630 | Injection, haloperidol, up to 5 mg | 6,025 | 4,876 | $13.56 |
| 88341 | 50 | 37 | $12.86 | |
| J3590 | Unclassified biologics | 2,827 | 767 | $11.99 |
| J1956 | Injection, levofloxacin, 250 mg | 1,520 | 1,258 | $10.66 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 1,306 | 1,108 | $10.50 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1,325 | 558 | $10.44 |
| J1790 | Injection, droperidol, up to 5 mg | 1,459 | 1,252 | $8.90 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 3,180 | 2,864 | $8.62 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 152 | 97 | $7.64 |
| J9045 | Injection, carboplatin, 50 mg | 2,853 | 1,755 | $6.66 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 413 | 363 | $6.42 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 1,682 | 833 | $6.13 |
| J3411 | Injection, thiamine hcl, 100 mg | 2,570 | 1,644 | $5.58 |
| J0456 | Injection, azithromycin, 500 mg | 2,160 | 1,108 | $5.58 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 1,083 | 950 | $5.18 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 1,189 | 1,045 | $3.38 |
| A4467 | Belt, strap, sleeve, garment, or covering, any type | 296 | 252 | $2.04 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 17 | 13 | $1.83 |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 1,004 | 481 | $1.70 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 5,092 | 4,338 | $1.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 438 | 401 | $0.79 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 621 | 580 | $0.76 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 819 | 739 | $0.46 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 1,225 | 583 | $0.44 |
| 91312 | 13 | 13 | $0.03 | |
| 91303 | 22 | 21 | $0.01 | |
| A6206 | Contact layer, sterile, 16 sq. in. or less, each dressing | 1,962 | 876 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 3,718 | 3,532 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 342 | 307 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 1,377 | 1,272 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 223 | 177 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 2,126 | 1,552 | $0.00 |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 625 | 334 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 766 | 574 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 1,025 | 813 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 1,814 | 1,620 | $0.00 |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | 506 | 232 | $0.00 |
| C1776 | Joint device (implantable) | 1,119 | 1,022 | $0.00 |
| A6010 | Collagen based wound filler, dry form, sterile, per gram of collagen | 197 | 105 | $0.00 |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 134 | 81 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 159 | 144 | $0.00 |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 1,023 | 915 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 2,117 | 1,830 | $0.00 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 334 | 203 | $0.00 |
| C1788 | Port, indwelling (implantable) | 168 | 157 | $0.00 |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | 73 | 68 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 200 | 133 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 234 | 181 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 68 | 65 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 46 | 40 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 447 | 296 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 62 | 60 | $0.00 |
| C1876 | Stent, non-coated/non-covered, with delivery system | 31 | 24 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 38 | 24 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 16 | 12 | $0.00 |
| 69210 | 12 | 12 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 43 | 15 | $0.00 |
| J1800 | Injection, propranolol hcl, up to 1 mg | 14 | 12 | $0.00 |
| J3415 | Injection, pyridoxine hcl, 100 mg | 27 | 14 | $0.00 |
| 92978 | 13 | 12 | $0.00 | |
| 82610 | 13 | 12 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 1,249 | 1,077 | $0.00 |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 130 | 50 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 844 | 742 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 625 | 576 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 2,920 | 1,253 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 1,610 | 1,483 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 3,519 | 1,365 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 289 | 192 | $0.00 |
| A9567 | Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries | 1,067 | 982 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 3,344 | 2,979 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 317 | 278 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 434 | 390 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 105 | 101 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 386 | 357 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 1,472 | 1,161 | $0.00 |
| 88300 | 18 | 16 | $0.00 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 103 | 68 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 34 | 31 | $0.00 |
| J2150 | Injection, mannitol, 25% in 50 ml | 67 | 29 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 611 | 581 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 198 | 162 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 613 | 536 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 186 | 174 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 454 | 405 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 304 | 291 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 125 | 115 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 44 | 44 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 669 | 572 | $0.00 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 55 | 40 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 56 | 52 | $0.00 |
| C1778 | Lead, neurostimulator (implantable) | 14 | 14 | $0.00 |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 99 | 65 | $0.00 |
| 76377 | 28 | 25 | $0.00 | |
| J9181 | Injection, etoposide, 10 mg | 50 | 12 | $0.00 |
| C2623 | Catheter, transluminal angioplasty, drug-coated, non-laser | 58 | 52 | $0.00 |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 83 | 77 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 551 | 346 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 184 | 169 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 78 | 60 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 103 | 93 | $0.00 |
| 88331 | 28 | 28 | $0.00 | |
| C2618 | Probe/needle, cryoablation | 28 | 24 | $0.00 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | 25 | 20 | $0.00 |
| G0010 | Administration of hepatitis b vaccine | 34 | 28 | $0.00 |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | 94 | 72 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 36 | 34 | $0.00 |
| L0150 | Cervical, semi-rigid, adjustable molded chin cup (plastic collar with mandibular/occipital piece) | 28 | 27 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 366 | 110 | $0.00 |
| 87593 | 34 | 29 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 51 | 44 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 17 | 12 | $0.00 |
| 88334 | 18 | 12 | $0.00 | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 76 | 14 | $0.00 |